Re-Defining Innovation in Pain Therapy: A Conversation with King's Management Team
This article was originally published in RPM Report
Executive Summary
King Pharmaceuticals is pursuing an interesting business model for pain therapy: driving abuse-resistance via continual innovation in formulation technology. It might be a home run in the current regulatory climate-provide King can stay on the right side of the regulators itself. We sat down with King CEO Brian Markison and Chief Scientist Eric Carter during the JP Morgan health care conference in January.
You may also be interested in...
Regulatory Alchemy: The Transformative Power of the Opioid REMS
The three-year long process towards a class-wide Risk Evaluation & Mitigation Strategy has been anything but straightforward. Still, the final twist may be the most surprising: FDA is now espousing the most industry-friendly approach on the table. The details of the opioid REMS will take months to work out and years to judge, but understanding the choices made in crafting this policy are a critical starting point.
King of Pain: Pfizer's Move into Abuse Resistant Opioids and the Virtues of Massive Scale
Pfizer’s $3.3 billion acquisition of King eliminates the primary opportunity for investors to play in the abuse-resistant formulation space and renewed questions about the logic of perpetual expansion atop Big Pharma. But the realities of the abuse resistant marketplace suggest it makes a good case for scale and diversity. Is this a sign of things to come in other drug classes?
King of Pain: Pfizer's Move into Abuse Resistant Opioids and the Virtues of Massive Scale
Pfizer’s $3.3 billion acquisition of King eliminates the primary opportunity for investors to play in the abuse-resistant formulation space and renewed questions about the logic of perpetual expansion atop Big Pharma. But the realities of the abuse resistant marketplace suggest it makes a good case for scale and diversity. Is this a sign of things to come in other drug classes?